Biotech investing and 2021’s carnage backdrop
The Covid cases are rising again, but we hope we will tackle the issue within this year-end. The pain of taking vaccine jab should be over; at least, that’s what we can expect. Nevertheless, Tech News Hub brings you excellent news regarding biotech.
Biotech is typically a phenomenon where science and biology come together. Though biology is a part of science, it receives extra attention when working with high tech. The biotechnology industry includes drug development and medical conditions companies whose products go under rigorous, costly and time-consuming processes. Clinical trials before getting approval by the US Food and Drug Administration (FDA) is crucial.
Have you ever heard of Liquid Death? No, it’s not actual death but a water brand. The brand is becoming so popular that it managed to raise $75 million in a single fundraiser in a week. Now you might ask what’s in the water that needs this kind of funding. We don’t know. Though Liquid Death is going for the ‘it kills thirst’ motto with name branding, and is quite successful.
Years ago, it was not that costly to build a startup. But why now? What’s in the water is that it would require millions of dollars into venture capital. To date, the company managed to raise $130 million, according to TechCrunch.
Another company called Level for funding small or micro-businesses raised more than $1.5 million in a week for bringing ‘credit to workers.’ But before closing 2021 fully, the company managed to score another $7 million in Series A funding. Anthos Capital led the Series A funding with NextView Ventures. Right after the expansion of the company, funding capital came in.
According to scientists, it is the ‘golden age of biotechnology. As we have more computing power in our hands than ever with the urge to grow more, biotech is advancing towards new ways of creativity. These ways were once imaginable only to treat diseases. Vaccinations or curing of disease took decades, and that was only a few years ago. Now artificial intelligence, machine learning, deep learning have taken them responsibly.
PsyMed Ventures, a biotech front, raised $25 million funding initially closed at $8 million. Among investing partners, Greg Kubin, Dina Burkitbayeva and Matias Serebrinsky were the first. The group started working together for longer than PsyMed and formed AngelList tech to invest around another $15 million to date. With the cash flow, the biotech firm is multiplying.
At the moment, if we look at biotech stocks on NASDAQ, Axsome Therapeutics (AXSM), with a $1.75 billion market cap, focusing on Neuroscience is a great option. Elexixis (EXEL), a valuation of $5.3 billion, which focuses on cancer, has excellent stock options. Not only do you get to benefit from the stocks, but being part of a biotech research facility ensures you’re a part of the development. Though we are not your financial advisers, take the information with a grain of salt.
Novavax (NVAX), valued with $16.6 billion for infectious diseases like coronavirus, has good stock options. Regeneron Pharmaceuticals (REGN), focusing on autoimmune diseases, cancer, eye disease, infectious disease has a market capitalisation of $81.4 billion. Last but not least, Vertex Pharmaceuticals (VRTX) has a market cap of $51.8 billion and researches rare diseases.
As much as we want to expand upon these top tier biotech stocks or companies, the article will become much longer than what we usually do. But with the hope to cover them in future, biotech pharmaceuticals are nevertheless great options for stock seekers. Take opinions from your trusted brokers as we are just passing the information upon research.
